**State-of-the-art lecture** *Proteomics in bladder cancer: Possibilities and perspectives*
A. Vlahou, Athens (GR)

* 936

**RNA sequencing identifies 3 different molecular grades and immune checkpoint cascades with distinct clinical behaviour in non-muscle invasive bladder cancer**

By: Chandrasekar T.¹, Zlotta A.¹, Shen J.², Noon A.³, Jiang H.⁴, Ehrlich A.⁵, Kuk C.⁵, Ni R.⁶, Sukhu B.⁶, Chan K.⁶, Roupret M.⁷, Seisen T.⁷, Comperat E.⁸, Sweet J.⁹, Kulkarni G.¹, Fleshner N.¹, Azad A.⁶, Van Der Kwast T.⁹, Wrana J.⁶

¹University of Toronto, Dept. of Surgical Oncology, Toronto, Canada, ²Mount Sinai Hospital, Dept. of Urology, Sheffield, United Kingdom, ³University Health Network, Dept. of Statistics, Toronto, Canada, ⁴University of Toronto, Dept. of Surgical Oncology, Toronto, Canada, ⁵Mount Sinai Hospital, Dept. of Pathology, Toronto, Canada, ⁶Université Pierre et Marie Curie, Dept. of Urology, Paris, France, ⁷University Pierre et Marie Curie, Dept. of Pathology, Paris, France, ⁸University Health Network, Dept. of Pathology, Toronto, Canada

937

**Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer**

By: Zhu Y., Liu Z., Fu H., Zhang J., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

938

**Long term results of BCG Tokyo and GMCSF-IFNa gene therapy in an orthotopic model of bladder cancer**

By: Esuvaranathan K.¹, Tham S.M.², Mahendran R.²

¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University of Singapore, Dept. of Surgery, Singapore, Singapore

939

**Stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer**
**940**

**A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I in bladder cancer**


1Oyokyo Kidney Research Institute, Cancer Immunology and Cell Biology, Hirosaki, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 3Shizuoka Cancer Center, Dept. of Anatomic Pathology, Shizuoka, Japan, 4Hirosaki University Graduate School of Medicine, Glycotechnology, Hirosaki, Japan, 5Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan

---

**941**

**Intravesical instillation of chemotherapeutic agents enhances immunomodulation of tumor microenvironment status in conventional BCG therapy**


Nara Medical University, Dept. of Urology, Nara, Japan

---

**942**

*The chemokine IP10 (CXCL10) dominates the long-term immune response stimulated by BCG treatment of non-muscle invasive bladder cancer, but a high concentration of IP10 in urine is strongly indicative of risk for the development of intolerance to BCG*


1Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, 2Institute for Biological Standards and Control (MHRA-NIBSC), Division of Bacteriology, Medicines and Healthcare products Regulatory Agency-National, Potters Bar, United Kingdom, 3National Centre for Biotechnology, CNB-CSIC, Dept. of Immunology and Oncology, Madrid, Spain, 4Hospital Universitario Infanta Sofia, Dept. of Urology, Madrid, Spain

---

**943**

**Latent viral infection as a factor of unfavorable prognosis of bladder cancer**


1Moscow City Hospital named by V.P Demikhov, Dept. of Urology, Moscow, Russia, 2Russian Medical Academy of Postgraduated Continuous Education, Dept. of Urology, Moscow, Russia, 3Moscow City Hospital named by V.P Demikhov, Dept. of Pathology, Moscow, Russia, 4Komi Republican Oncologic Hospital, Dept. of Urology, Syktyvkar, Russia, 5Moscow City Hospital named by V.P Demikhov, Dept. of Urology, Moscow, Russia, 6The Vologda Regional Clinical Hospital № 2, Dept. of Pathology, Cherepovec, Russia
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>944</td>
<td>Association between inflammatory potential in diet and bladder cancer risk: Results from three US prospective cohort studies</td>
<td>Abufaraj M. 1, Tabung F. 2, Shariat S. 3, Moschini M. 4, Devore E. 5, Zhang X. 5, Papantoniou K. 6, Yang L. 6, Strohmaier S. 5, Rohrer F. 6, Markt S. 7, Zhang X. 7, Giovannucci E. 7, Schernhammer E. 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2Harvard T.H Chan School of Public Health, Dept. of Nutrition, Boston, United States of America, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 5Harvard Medical School, Dept. of Medicine, Boston, United States of America, 6Medical University of Vienna, Dept. of Epidemiology, Vienna, Austria, 7Harvard T.H Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America</td>
</tr>
<tr>
<td>945</td>
<td>Rationale and possibility of intravesical Bacillus Calmette-Guerin therapy with cytokine against bladder cancer</td>
<td>Takeuchi A., Shiota M., Kamiryo Y., Tatsugami K., Eto M.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan</td>
</tr>
<tr>
<td>946</td>
<td>High-penetrating, target-releasing drug delivery system based on dendritic nanoparticles for intravesical instillation</td>
<td>Qiu X. 1, Cao K. 1, Lin T. 1, Chen W. 1, Yuan A. 2, Wu J. 2, Guo H. 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China, 2Medical School of Nanjing University, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing, China</td>
</tr>
<tr>
<td>947</td>
<td>Urothelial bladder cancer cells affect tumor-promoting processes in normal bladder fibroblasts and support tumorigenesis by secretion of tumor-associated exosomes</td>
<td>Baumgart S. 1, Heinzelmann J. 1, Krause E. 2, Stoeckle M. 1, Junker K. 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany, 2Saarland University Medical Center, Dept. of Physiology, Homburg, Germany</td>
</tr>
</tbody>
</table>